Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of an Omicron-strain inactivated COVID-19 vaccine in unvaccinated adults
ChiCTR2200062420Phase 3Not yet recruiting
- Sponsor
- Beijing Friendship Hospital
- Start
- Jul 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of Omicron strain inactivated COVID-19 vaccine (Vero cells) in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Beijing Friendship Hospital. Primary endpoint: Geometric mean titer and 4-fold rise rate of anti-Omicron neutralizing antibodies. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
Omicron strain inactivated COVID-19 vaccine (Vero cells)
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2200062420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062420.